Development of novel dual Insulin-like Growth Factor-1 Receptor (IGF-1R)/ Epidermal Growth Factor Receptor (EGFR) inhibitors for treatment of Ewing’s sarcoma

Posted on:
William Bornmann, PhD,  MD Anderson Cancer Center
Recipient of the: $25,000 Mary Beth Knox Memorial Research Award

Ewing’s sarcoma, a devastating disease in children and young adults, is in great need for a therapy.  Insulin-like Growth Factor type 1Receptor (IGF-1R) and Epidermal Growth Factor Receptor (EGFR) proved to be interesting targets for different sarcomas.  Here we proposed the development and synthesis of novel dual IGF-1R/EGFR inhibitors based on virtual screening.  We hypothesize that simultaneous targeting of the two receptor tyrosine kinases will be an efficient treatment for Ewing’s sarcoma.  Inhibitory activity and selectivity of the inhibitors will be determined in vitro.